United States Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012

Published by: Global Markets Direct

Published: Sep. 30, 2008 - 219 Pages

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 What Is This Report About?

2.2 Definitions

2.2.1 Drug delivery devices

2.2.1.1 Needle-free Injections

2.2.1.2 Inhalation Systems

2.2.1.3 Infusion Systems

3 Healthcare Sector Review

3.1 Healthcare Expenditure

3.2 Healthcare Infrastructure

3.2.1 Healthcare Personnel Data

3.2.2 Healthcare Facilities Data

4 Drug Delivery Devices in United States.

4.1 Drug Delivery Devices Overall Revenues (2000-2012)

4.2 Drug Delivery Devices Overall Volume (2000-2012)

4.3 Drug Delivery Devices Overall Company Shares (2005-2006)

5 Inhalation System in United States

5.1 Inhalation Systems Overall Revenues (2000-2012)

5.1.1 Metered Dose Inhalation Systems Overall Revenues (2000-2012)

5.1.2 Dry Powder Inhalation Systems Overall Revenues (2000-2012)

5.2 Inhalation Systems Overall Volume (2000-2012)

5.2.1 Metered Dose Inhalation Systems Overall Volume (2000-2012)

5.2.2 Dry Powder Inhalation Systems Overall Volume (2000-2012)

5.3 Inhalation Systems Average Price (2000-2012)

5.3.1 Metered Dose Inhalation Systems Average Price (2000-2012)

5.3.2 Dry Powder Inhalation Systems Average Price (2000-2012)

5.4 Inhalation Systems Distribution Share (2005-2006)

5.5 Inhalation Systems Company Share (2005-2006)

6 Infusion System in United States

6.1 Infusion Systems Overall Revenues (2000-2012)

6.1.1 Infusion Disposable Sets Infusion System Overall Revenues (2000-2012)

6.1.2 Infusion Pumps Infusion System Overall Revenue (2000-2012)

6.1.3 Syringe Pumps Infusion System Overall Revenue (2000-2012)

6.2 Infusion Systems Overall Volume (2000-2012)

6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)

6.2.2 Infusion Pumps Overall Volume (2000-2012)

6.2.3 Syringe Pumps Overall Volume (2000-2012)

6.3 Infusion Systems Average Price (2000-2012)

6.3.1 Infusion Pumps Average Price (2000-2012)

6.3.2 Syringe Pumps Average Price (2000-2012)

6.3.3 Infusion Disposable Sets Average Price (2000-2012)

6.4 Infusion Systems Distribution Share (2005-2006)

6.5 Infusion Systems Company Share (2005-2006)

7 Needle Free Injections in United States

7.1 Needle Free Injections Overall Revenue (2000-2012)

7.2 Needle Free Injections Category Volume (2000-2012)

7.3 Needle Free Injections Average Price (2000-2012)

7.4 Needle Free Injections Distribution Share (2005-2006)

7.5 Needle Free Injections Company Share (2005-2006)

8 AstraZeneca PLC Company Profile

8.1 Company Overview

8.2 Business Overview

8.2.1 Products

8.2.2 History

8.3 Locations And Subsidiaries

8.4 Financial Deals Landscape

8.4.1 AstraZeneca Completes $6,900 Million Private Placement

8.4.2 AstraZeneca Acquires MedImmune

8.4.3 AstraZeneca Acquires Biologics Manufacturing Facility From DSM Biologics

8.4.4 AstraZeneca Acquires Arrow Therapeutics

8.4.5 AstraZeneca Signs An Agreement With Palatin Technologies

8.4.6 AstraZeneca Signs An Agreement With Bristol-Myers Squibb

8.4.7 AstraZeneca Signs An Agreement With Cubist Pharmaceuticals

8.4.8 AstraZeneca Signs An Agreement With Par Pharmaceutical

8.4.9 Schering Signs An Agreement With AstraZeneca

8.4.10 AstraZeneca Signs An Agreement With Pozen

8.4.11 AstraZeneca Signs An Agreement With Abbott

8.4.12 AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product Portfolio To Abraxis BioScience

8.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals

8.4.14 AstraZeneca Acquires A Stake In Protherics

8.4.15 AstraZeneca Signs An Agreement With Targacept

8.4.16 AstraZeneca Signs An Agreement With AtheroGenics

8.4.17 AstraZeneca UK Signs An Agreement With Protherics

8.4.18 AstraZeneca Signs An Agreement With Bayer Schering Pharma Aktiengesellschaft

8.4.19 AstraZeneca Signs An Agreement With Astex Therapeutics

8.4.20 AstraZeneca Signs An Agreement With Avanir Pharmaceuticals

8.4.21 AstraZeneca And Royal Cosun Sells Joint Venture Advanta To Syngenta

8.4.22 AstraZeneca Completes Private Placement Of $750 million

8.4.23 AstraZeneca Prices EUR750 Million Private Placement

8.4.24 AstraZeneca Prices Sterling Bond GBP350 Million And Euro750 Million Eurobond Private Placement

8.5 Recent Developments

8.5.1 Feb 22, 2008: AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case

8.5.2 Feb 18, 2008: AstraZeneca Appoints Non-Executive Director

8.5.3 Dec 12, 2007: AstraZeneca Files Patent Infringement Actions in Response to Crestor ANDAs

8.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO

8.5.5 Jul 25, 2007: AstraZeneca Appoints New Board Member

8.5.6 Jun 06, 2007: AstraZeneca CFO Resigns

8.5.7 Feb 22, 2007: AstraZeneca To Invest $120 Miilion For R&D In Macclesfield Site

8.5.8 Jan 30, 2007: Philips And Leading Healthcare Companies Join For Major Research And Development

8.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million Research Investment In Boston

9 GlaxoSmithKline plc Company Profile

9.1 Company Overview

9.2 Business Overview

9.2.1 Products

9.2.2 History

9.3 Locations And Subsidiaries

10 3M Company Profile

10.1 Company Overview

10.2 Business Overview

10.2.1 Consumer and Office

10.2.2 Display and Graphics

10.2.3 Electro and Communications

10.2.4 Health Care

10.2.5 Industrial and Transportation

10.2.6 Safety, Security and Protection Services

10.2.7 Products

10.3 Value Chain Analysis

10.3.1 Manufacturing

10.3.2 Product Development

10.3.3 Sales and Marketing

10.4 SWOT Analysis

10.4.1 3M Company Strengths

10.4.2 3M Company Weaknesses

10.4.3 3M Company Opportunities

10.4.4 3M Company Threats

10.5 Financial and Operational Review

10.6 Locations And Subsidiaries

11 Baxter International Company Profile

11.1 Company Overview

11.2 Business Overview

11.2.1 BioScience

11.2.2 Medication Delivery

11.2.3 Renal

11.2.4 Products

11.2.5 History

11.3 Value Chain Analysis

11.3.1 Manufacturing

11.3.2 Product Development

11.3.3 Sales and Marketing

11.4 SWOT Analysis

11.4.1 Baxter International Inc. Strengths

11.4.2 Baxter International Inc. Weaknesses

11.4.3 Baxter International Inc. Opportunities

11.4.4 Baxter International Inc. Threats

11.5 Financial and Operational Review

11.6 Locations And Subsidiaries

11.7 Baxter International Inc. Pipeline Products

11.7.1 Next-Generation Home Hemodialysis Machine

11.7.1.1 Product Overview

11.7.1.2 Product Description

11.7.1.3 Product Status

11.7.1.4 Product Milestone

12 Hospira Company Profile

12.1 Company Overview

12.2 Business Overview

12.2.1 Injectable Pharmaceutical Custom Manufacturing Services Product Category

12.2.2 Other products, including critical care devices Product Category

12.2.3 Specialty Injectable Pharmaceuticals Product Category

12.2.4 Products

12.3 History

12.4 Value Chain Analysis

12.4.1 Manufacturing

12.4.2 Product Development

12.4.3 Sales and Marketing

12.5 SWOT Analysis

12.5.1 Hospira, Inc. Strengths

12.5.2 Hospira, Inc. Weaknesses

12.5.3 Hospira, Inc. Opportunities

12.5.4 Hospira, Inc. Threats

12.6 Financial and Operational Review

12.7 Locations And Subsidiaries

13 Regulation System

13.1 Medical Equipment Approval Process

13.1.1 Pre-market Approval Process

13.1.2 Intended use and Indications for use

13.1.3 Predicate Device

13.1.4 Safe and Effective

13.1.5 Other Category Devices

13.1.6 Post-Market Approval Process

13.1.7 Compliance and Enforcement

13.1.8 Registration Fee

13.1.9 Approval Time

14 Pricing and Reimbursement

14.1 Government Policies

14.2 Private Insurance

14.3 Diagnosis Related Groups (DRG)

15 Distribution Structure

15.1 Distribution Structure

16 Financial Deals Landscape

16.1 Private Equity

16.1.1 Warburg Pincus Acquires Lifecore Biomedical

16.2 Venture Financing

16.2.1 POINT Biomedical Secures $25 Million In Venture Financing

16.2.2 Medipacs Secures $1.65 Million In Financing Round

16.2.3 AcelRx Pharmaceuticals Secures $20.21 Million In Venture Financing

16.2.4 TyRx Pharma Secures $25 Million In Venture Financing

16.2.5 Oriel Therapeutics Secures $23 Million In Series C Funding

16.3 IPO

16.3.1 MannKind Corporation Completes Private Placement Of $250 Million

16.3.2 Delcath Systems Completes Private Placement Of $14.2 Million

16.4 Debt Offerings

16.4.1 Bioject Medical Completes Private Placement $1.21 Million

16.5 Partnership

16.5.1 Lupin Enters Into An Agreement With Forest Laboratories

16.5.2 Aethlon Medical And Delcath Systems Form Joint Venture

16.6 Asset Transactions

16.6.1 Orthofix International Sells Its Pain Care Assets To LMA International

16.6.2 Boston Scientific Sells Auditory Business And Drug Pump Development Program To Former Shareholders Of Advanced Bionics

17 Recent Developments

17.1 Strategy And Business Planning

17.1.1 Sep 02, 2008: Alpha Innotech And GE Healthcare Announce Strategic Alliance Partnership

17.1.2 Aug 28, 2008: 3M Acquires Texas Based Polyfoam

17.1.3 Apr 08, 2008: BD Opens New Manufacturing Facility In Suzhou, China

17.2 Corporate Communications

17.2.1 May 29, 2008: Alexza Appoints VP, International Development Operations

17.2.2 May 22, 2008: Nektar Appoints New COO

17.2.3 May 19, 2008: Alexza Appoints New President To Its subsidiary

17.2.4 May 15, 2008: Sepracor Appoints New CFO

17.2.5 May 15, 2008: Sepracor CFO To Resign

17.2.6 May 15, 2008: Alexza Appoints New Vice President, Quality

17.2.7 May 13, 2008: Vyteris Appoints President And CFO

17.2.8 May 13, 2008: Hospira Expands Board Of Directors

17.2.9 May 08, 2008: Inovio Elects New Director

17.2.10 May 06, 2008: Echo Appoints Medical Advisory Board Member

17.2.11 Apr 02, 2008: Duska Appoints Scientific Advisory Board Member

17.2.12 Mar 18, 2008: BD Elects Vice Chairman And Board Member

17.3 Legal and Regulatory

17.3.1 Aug 19, 2008: Coughlin Stoia Files Class Action Law Suit Against Inyx

17.4 Product News

17.4.1 Sep 09, 2008: Navilyst Medical Introduces New EZ Huber Safety Infusion Set

18 Appendix

18.1 Methodology

18.2 Currency Conversion

18.3 Contact Us

18.4 Disclaimer

1.1 List of Tables

Table 1: United States Healthcare Expenditure, 2003-2010

Table 2: United States Healthcare Expenditure by Age (per person), 2000-2003

Table 3: United States Healthcare Expenditure by Sex (per person), 2000-2003

Table 4: United States Healthcare Expenditure by Race (per person), 2000-2003

Table 5: United States Personal Healthcare Expenditure by Type, 2000-2004

Table 6: United States Personal Healthcare Expenditure by Source, 2000-2004

Table 7: Total Number of Doctors in the United States, 2003-2010

Table 8: Number of Doctors by Specialty in the United States, 2003-2010

Table 9: Doctors by Region (Number per 10,000 Civilian Population), 2002-2004

Table 10: Doctors by Region (Number per 10,000 Civilian Population), 2002-2004 (Cont.)

Table 11: Total Hospitals in the United States, 2000-2004

Table 12: Community Hospitals by Number of Beds in the United States, 2000-2004

Table 13: Number of Hospital Beds in the United States, 2000-2004

Table 14: Number of Hospital Beds by Range in the United States, 2000-2004

Table 15: Drug Delivery Devices, United States, Overall Revenues ($ mn), 2000-2012

Table 16: Drug Delivery Devices, United States, Overall Revenues ($ mn), Historic, 2000-2007

Table 17: Drug Delivery Devices, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Table 18: Drug Delivery Devices, United States, Category Revenues ($ mn), 2000-2012

Table 19: Drug Delivery Devices, United States, Category Revenues ($ mn), Historic, 2000-2007

Table 20: Drug Delivery Devices, United States, Category Revenues ($ mn), Forecast, 2007-2012

Table 21: Drug Delivery Devices, United States, Category Volume (Units), 2000-2012

Table 22: Drug Delivery Devices, United States, Category Volume (Units), Historic, 2000-2007

Table 23: Drug Delivery Devices, United States, Category Volume (Units), Forecast, 2007-2012

Table 24: Drug Delivery Devices, United States, Overall, Company Share by Revenue ($ mn), 2005-2006

Table 25: Inhalation Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007

Table 26: Inhalation Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Table 27: Inhalation Systems, United States, Revenue by Segment ($ mn), Historic, 2000-2007

Table 28: Inhalation Systems, United States, Revenue by Segment ($ mn), Forecast, 2007-2012

Table 29: Metered Dose Inhalation Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007

Table 30: Metered Dose Inhalation Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Table 31: Dry Powder Inhalation Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007

Table 32: Dry Powder Inhalation Systems, United States, Overall Revenues ($ mn), Forecast, 2000-2007

Table 33: Inhalation Systems, United States, Overall Volume (Units), Historic, 2000-2007

Table 34: Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012

Table 35: Metered Dose Inhalation Systems, United States, Overall Volume (Units), Historic, 2000-2007

Table 36: Metered Dose Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012

Table 37: Dry Powder Inhalation Systems, United States, Overall Volume (Units), Historic, 2000-2007

Table 38: Dry Powder Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012

Table 39: Metered Dose Inhalation Systems, United States, Average Price ($), Historic, 2000-2007

Table 40: Metered Dose Inhalation Systems, United States, Average Price ($), Forecast, 2007-2012

Table 41: Dry Powder Inhalation Systems, United States, Average Price ($), Historic, 2000-2007

Table 42: Dry Powder Inhalation Systems, United States, Average Price ($), Forecast, 2007-2012

Table 43: Inhalation Systems, United States, Distribution Share by Revenue ($ mn), 2005-2006

Table 44: Inhalation Systems, United States, Company Share by Revenue ($ mn), 2005-2006

Table 45: Infusion Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007

Table 46: Infusion Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Table 47: Infusion Systems, United States, Revenue by Segment ($ mn), Historic, 2000-2007

Table 48: Infusion Systems, United States, Revenue by Segment ($ mn), Forecast, 2007-2012

Table 49: Infusion Disposable Sets, United States, Overall Revenues ($ mn), Historic, 2000-2007

Table 50: Infusion Disposable Sets, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Table 51: Infusion Pumps, United States, Overall Revenues ($ mn), Historic, 2000-2007

Table 52: Infusion Pumps, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Table 53: Syringe Pumps, United States, Overall Revenues ($ mn), Historic, 2000-2007

Table 54: Syringe Pumps, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Table 55: Infusion Systems, United States, Overall Volume (Units), Historic, 2000-2007

Table 56: Infusion Systems, United States, Overall Volume (Units), Forecast, 2007-2012

Table 57: Infusion Disposable Sets, United States, Overall Volume (Units), Historic, 2000-2007

Table 58: Infusion Disposable Sets, United States, Overall Volume (Units), Forecast, 2007-2012

Table 59: Infusion Pumps, United States, Overall Volume (Units), Historic, 2000-2007

Table 60: Infusion Pumps, United States, Overall Volume (Units), Forecast, 2007-2012

Table 61: Syringe Pumps, United States, Overall Volume (Units), Historic, 2000-2007

Table 62: Syringe Pumps, United States, Overall Volume (Units), Forecast, 2007-2012

Table 63: Infusion Pumps, United States, Average Price ($), Historic, 2000-2007

Table 64: Infusion Pumps, United States, Average Price ($), Forecast, 2007-2012

Table 65: Syringe Pumps, United States, Average Price ($), Historic, 2000-2007

Table 66: Syringe Pumps, United States, Average Price ($), Forecast, 2007-2012

Table 67: Infusion Disposable Sets, United States, Average Price ($), Historic, 2000-2007

Table 68: Infusion Disposable Sets, United States, Average Price ($), Forecast, 2007-2012

Table 69: Infusion Systems, United States, Distribution Share by Revenue ($ mn), 2005-2006

Table 70: Infusion Systems, United States, Company Share by Revenue ($ mn), 2005-2006

Table 71: Needle Free Injections, United States, Overall Revenues ($ mn), Historic, 2000-2007

Table 72: Needle Free Injections, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Table 73: Needle Free Injections, United States, Overall Volume (Units), Historic, 2000-2007

Table 74: Needle Free Injections, United States, Overall Volume (Units), Forecast, 2007-2012

Table 75: Needle Free Injections, United States, Average Price ($), Historic, 2000-2007

Table 76: Needle Free Injections, United States, Average Price ($), Forecast, 2007-2012

Table 77: Needle Free Injections, United States, Distribution Share by Revenue ($ mn), 2005-2006

Table 78: Needle Free Injections, United States, Company Share by Revenue ($ mn), 2005-2006

Table 79: AstraZeneca PLC, Subsidiaries

Table 80: GlaxoSmithKline plc, Subsidiaries

Table 81: 3M Company, SWOT Analysis, 2006

Table 82: 3M Company, Financial Statements, USD Million, 2002-2006

Table 83: 3M Company, Financial Ratios, USD Million, 2002-2006

Table 84: 3M Company, Subsidiaries

Table 85: Baxter International Inc., SWOT Analysis, 2006

Table 86: Baxter International Inc., Financial Statements, USD Million, 2002-2006

Table 87: Baxter International Inc., Financial Ratios, USD Million, 2002-2006

Table 88: Baxter International Inc., Other Locations

Table 89: Baxter International Inc., Subsidiaries

Table 90: Hospira, Inc., SWOT Analysis, 2006

Table 91: Hospira, Inc., Financial Statements, USD Thousand, 2002-2006

Table 92: Hospira, Inc., Financial Ratios, USD Thousand, 2002-2006

Table 93: Hospira, Inc., Other Locations

Table 94: Medical Equipment Registration Fee in United States, 2007

Table 95: Medical Device Approval Time in United States, 2004

Table 96: Currency Conversion from USD to Local Currency at 2007 Constant Rate 2

1.2 List of Figures

Figure 1: United States, Healthcare Expenditure by Source, 2003

Figure 2: United States, Healthcare Infrastructure, Top Level View, 2007

Figure 3: Healthcare Expenses Segmentation by End User, 2003

Figure 4: Drug Delivery Devices, United States, Overall Revenues ($ mn), 2000-2012

Figure 5: Drug Delivery Devices, United States, Overall Revenues ($ mn), Historic, 2000-2007

Figure 6: Drug Delivery Devices, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 7: Drug Delivery Devices, United States, Category Revenues ($ mn), 2000-2012

Figure 8: Drug Delivery Devices, United States, Category Revenues ($ mn), Historic, 2000-2007

Figure 9: Drug Delivery Devices, United States, Category Revenues ($ mn), Forecast, 2007-2012

Figure 10: Drug Delivery Devices, United States, Overall Company Share (%), 2006

Figure 11: Inhalation Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007

Figure 12: Inhalation Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 13: Inhalation Systems, United States, Revenue by Segment ($ mn), Historic, 2000-2007

Figure 14: Inhalation Systems, United States, Revenue by Segment ($ mn), Forecast, 2007-2012

Figure 15: Metered Dose Inhalation Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007

Figure 16: Metered Dose Inhalation Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 17: Dry Powder Inhalation Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007

Figure 18: Dry Powder Inhalation Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 19: Inhalation Systems, United States, Overall Volume (Units), Historic, 2000-2007

Figure 20: Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012

Figure 21: Metered Dose Inhalation Systems, United States, Overall Volume (Units), Historic, 2000-2007

Figure 22: Metered Dose Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012

Figure 23: Dry Powder Inhalation Systems, United States, Overall Volume (Units), Historic, 2000-2007

Figure 24: Dry Powder Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012

Figure 25: Metered Dose Inhalation Systems, United States, Average Price ($), Historic, 2000-2007

Figure 26: Metered Dose Inhalation Systems, United States, Average Price ($), Forecast, 2007-2012

Figure 27: Dry Powder Inhalation Systems, United States, Average Price ($), Historic, 2000-2007

Figure 28: Dry Powder Inhalation Systems, United States, Average Price ($), Forecast, 2007-2012

Figure 29: Inhalation Systems, United States, Distribution Share (%), 2005-2006

Figure 30: Inhalation Systems, United States, Company Share (%), 2006

Figure 31: Infusion Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007

Figure 32: Infusion Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 33: Infusion Systems, United States, Revenue by Segment ($ mn), Historic, 2000-2007

Figure 34: Infusion Systems, United States, Revenue by Segment ($ mn), Forecast, 2007-2012

Figure 35: Infusion Disposable Sets, United States, Overall Revenues ($ mn), Historic, 2000-2007

Figure 36: Infusion Disposable Sets, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 37: Infusion Pumps, United States, Overall Revenues ($ mn), Historic, 2000-2007

Figure 38: Infusion Pumps, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 39: Syringe Pumps, United States, Overall Revenues ($ mn), Historic, 2000-2007

Figure 40: Syringe Pumps, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 41: Infusion Disposable Sets, United States, Overall Volume (Units), Historic, 2000-2007

Figure 42: Infusion Disposable Sets, United States, Overall Volume (Units), Forecast, 2007-2012

Figure 43: Infusion Pumps, United States, Overall Volume (Units), Historic, 2000-2007

Figure 44: Infusion Pumps, United States, Overall Volume (Units), Forecast, 2007-2012

Figure 45: Syringe Pumps, United States, Overall Volume (Units), Historic, 2000-2007

Figure 46: Syringe Pumps, United States, Overall Volume (Units), Forecast, 2007-2012

Figure 47: Infusion Pumps, United States, Average Price ($), Historic, 2000-2007

Figure 48: Infusion Pumps, United States, Average Price ($), Forecast, 2007-2012

Figure 49: Syringe Pumps, United States, Average Price ($), Historic, 2000-2007

Figure 50: Syringe Pumps, United States, Average Price ($), Forecast, 2007-2012

Figure 51: Infusion Disposable Sets, United States, Average Price ($), Historic, 2000-2007

Figure 52: Infusion Disposable Sets, United States, Average Price ($), Forecast, 2007-2012

Figure 53: Infusion Systems, United States, Distribution Share (%), 2006

Figure 54: Infusion Systems, United States, Company Share (%), 2006

Figure 55: Needle Free Injections, United States, Overall Revenues ($ mn), Historic, 2000-2007

Figure 56: Needle Free Injections, United States, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 57: Needle Free Injections, United States, Overall Volume (Units), Historic, 2000-2007

Figure 58: Needle Free Injections, United States, Overall Volume (Units), Forecast, 2007-2012

Figure 59: Needle Free Injections, United States, Average Price ($), Historic, 2000-2007

Figure 60: Needle Free Injections, United States, Average Price ($), Forecast, 2007-2012

Figure 61: Needle Free Injections, United States, Distribution Share (%), 2006

Figure 62: Needle Free Injections, United States, Company Share (%), 2006

Figure 63: 3M Company, Value Chain Analysis

Figure 64: Baxter International Inc., Value Chain Analysis

Figure 65: Hospira, Inc., Value Chain Analysis

Figure 66: Medical Equipment Approval Process in the United States, 2007

Figure 67: PMA Approval Process in the United States, 2007

Figure 68: The 510(k) Approval Process for Medical Devices in the United States, 2007

Figure 69: Reimbursement Structure in the United States, 2007

Figure 70: Distribution Structure of Medical Equipment in the United States, 2006 1

Abstract

• The report provides drug delivery devices information broken down into detailed categories and segments in United States.
• Total revenues, products sold, end users, and average pricing.
• Market shares of all the key competitors.
• Key pipeline products that are set to shape the market, broken down by sector.
• Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
• Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
• Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
• Key mergers and acquisitions, partnerships, private equity investments and IPOs.
• Customer, hospitals and physicians data.

• Gain a strong understanding of the drug delivery devices market in United States.
• Evaluate and compare the attractiveness of the market in the country.
• Identify growth segments and opportunities in each industry sector within the country.
• Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
• Analyze the competitiveness of the market in the country and identify hotspots.
• Develop strategies based on the latest product, brand, expansion and research and development news in the country.
• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
• Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.